Vital Therapies, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-01-01
- Employees
- 51
- Market Cap
- -
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
- Conditions
- Acute Alcoholic Hepatitis
- Interventions
- Biological: ELAD SystemOther: Standard of Care (Control)
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT02612428
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
🇦🇹Medizinische Universität Graz, Graz, Styria, Austria
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
- Conditions
- Surgically-Induced Liver FailureFulminant Hepatic FailurePrimary Graft Non-FunctionAcute Liver Failure
- Interventions
- Biological: ELAD
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01875874
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
- Conditions
- Severe Acute Alcoholic Hepatitis
- Interventions
- Biological: ELADOther: Standard of Care treatment
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01829347
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Johns Hopkins University Hospital, Bethesda, Maryland, United States
🇬🇧Royal Free Hospital, Hampstead, London, United Kingdom
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
- Conditions
- Acute Alcoholic Hepatitis
- Interventions
- Biological: ELAD treatmentOther: Standard of care (Control)
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT01471028
- Locations
- 🇬🇧
King's College Hospital, London, England, United Kingdom
🇺🇸Maricopa Integrated Health System (MIHS), Phoenix, Arizona, United States
🇺🇸University of Arizona Medical Center, Tucson, Arizona, United States
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
- Conditions
- Acute Liver Failure
- Interventions
- Drug: ELAD (Extracorporeal Liver Assist System)
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Vital Therapies, Inc.
- Registration Number
- NCT01452295
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis
- Conditions
- Acute On Chronic Hepatitis
- Interventions
- Biological: ELAD plus standard of care treatmentOther: Standard of care
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00973817
- Locations
- 🇬🇧
University Hospitals Birmingham, Birmingham, England, United Kingdom
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
- Conditions
- Liver Failure
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- Vital Therapies, Inc.
- Registration Number
- NCT00832273
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)
- Conditions
- Fulminant Hepatic Failure
- Interventions
- Other: Standard of CareDevice: ELAD®
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Vital Therapies, Inc.
- Registration Number
- NCT00832728
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
- Conditions
- Chronic HepatitisAcute Hepatitis
- Interventions
- Other: Standard of care treatmentBiological: ELAD plus standard of care treatment
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00771446
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
- Conditions
- Fulminant Hepatic Failure
- Interventions
- Biological: ELADOther: Standard of care (Control)
- First Posted Date
- 2002-02-12
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Vital Therapies, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00030225
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Emory School of Medicine, Atlanta, Georgia, United States